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Study Objectives: Neurocognitive deficits have been shown in school-aged children with sleep apnea. The effect of obstructive sleep apnea (OSA) on the 
neurodevelopmental outcome of preterm infants is unknown.
Methods: A retrospective chart review was performed for all preterm infants (< 37 weeks) who had neonatal polysomnography (PSG) and completed 
neurodevelopmental assessment with the Bayley Scales of Infant and Toddler Development, 3rd Edition, between 2006 to 2015 at Riley Hospital. Exclusion 
criteria included grade IV intraventricular hemorrhage, tracheostomy, cyanotic heart disease, severe retinopathy of prematurity, craniofacial anomalies, or 
central and mixed apnea on PSG. Sleep apnea was defined as an apnea-hypopnea index (AHI) > 1 event/h. Regression analyses were performed to find a 
relationship between PSG parameters and cognitive, language, and motor scores.
Results: Fifteen patients (males: n = 10) were eligible for the study. Median postmenstrual age at the time of the PSG was 41 weeks (37–46). Median AHI 
for the cohort was 17.4 events/h (2.2–41.3). Median cognitive, language, and motor scores were 90 (65–125), 89 (65–121), and 91 (61–112), respectively. 
Mean end-tidal CO2 (median 47 mm Hg [25–60]) negatively correlated with cognitive scores (P = .01) but did not significantly correlate with language or motor 
scores. AHI was not associated with cognitive, language, or motor scores.
Conclusions: The median score for cognitive, language, and motor scores for preterm infants with neonatal OSA were within one standard deviation of the 
published norm. Mean end-tidal CO2, independent of AHI, may serve as a biomarker for predicting poor cognitive outcome in preterm infants with neonatal OSA.
Commentary: A commentary on this article appears in this issue on page 1233.
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INTRODUCTION
Sleep plays an essential role in learning, memory consolida-
tion, and cognition.1 Sleep-disordered breathing (SDB) results 
in periods of occlusion of the upper airway during sleep, often 
associated with oxygen desaturations, arousals, and impaired 
sleep quality. SDB in preschool children has been associated 
with impaired executive functioning, attention, receptive 
vocabulary, and behavioral problems.2 Even in the absence 
of obstructive sleep apnea (OSA) as diagnosed by polysom-
nography (PSG), SDB symptoms have been associated with 
reduced executive function and memory skills in 5-year-old 
children.3 Reduction in nocturnal arousals in preschool chil-
dren with SDB was associated with improved attention and 
aggressive behavior.4 There is a strong association of SDB 
with deficits in cognitive abilities and academic achievement 
during school age, particularly in those who were born pre-
term.5 Sleep apnea clearly has significant developmental and 
behavioral implications, and because children born preterm 
are more likely to receive a diagnosis of sleep apnea, com-
pared to children born full term,6 it is important to assess the 
association of sleep apnea with neurocognitive outcomes in 
this population.
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Preterm infants are at high risk for suboptimal neurodevel-
opmental outcomes on account of a host of neonatal comor-
bidities and disrupted neuronal maturation.7 Risk factors for 
poor neurodevelopment include low gestational age, birth 
weight, presence of bronchopulmonary dysplasia (BPD), nec-
rotizing enterocolitis (NEC), severe neurological injury, pul-
monary hypertension, sepsis, absence of antenatal steroids, 
patent ductus arteriosus (PDA) ligation, prolonged ventila-
tion, prolonged total parenteral nutrition, and postnatal growth 
BRIEF SUMMARY
Current Knowledge/Study Rationale: Preterm infants are an 
at-risk population for poor neurodevelopmental outcomes as well 
as sleep-disordered breathing (SDB). Sleep apnea has significant 
developmental and behavioral implications; however, the effect of 
neonatal SDB on the neurodevelopmental outcomes of preterm 
infants is unknown.
Study Impact: Although there is a high level of SDB in preterm 
infants, the median score for cognitive, language and motor scores 
were still within one standard deviation of the published norm. 
Mean end-tidal CO2, independent of apnea-hypopnea index, in 
polysomnography may be worth consideration as a biomarker for 
predicting poor cognitive outcome in this high-risk population.
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retardation.8–14 In addition to medical morbidities, preterm in-
fants have reduced cerebral oxygenation during active sleep at 
post-term corrected age.15 Preterm infants with SDB and as-
sociated sleep disruption may be at increased risk of reduced 
cerebral oxygenation. However, the effect of neonatal OSA on 
the neurodevelopmental outcomes of preterm infants is un-
known. Capnography during PSG is challenging,16 particularly 
in neonates. Although existing literature suggests no effect of 
permissive hypercapnia, during the first few days of life, on 
neurodevelopmental outcome,17,18 there are no published data 
on the effect of sustained hypercapnia during sleep on neuro-
cognitive outcomes in preterm infants.
The aim of our study was to assess cognitive/motor and lan-
guage development at 2 years of age in preterm infants with 
documented neonatal OSA. Our hypothesis was that the sever-
ity of neonatal OSA would correlate with worsening cognitive, 
motor, and language development.
METHODS
This is a retrospective study evaluating preterm infants (< 37 
weeks) cared for at Riley Hospital for Children at IU Health 
who received neonatal PSG between January 2006 and Au-
gust 2015 prior to discharge from the neonatal intensive care 
unit and completed neurodevelopmental assessment with the 
Bayley Scales of Infant and Toddler Development, 3rd Edition 
(BSID-III), at 2 years of age at the Indiana University New-
born Follow-up Program. Exclusion criteria included grade IV 
intraventricular hemorrhage, tracheostomy, severe retinopathy 
of prematurity (stage 4 and stage 5), cyanotic heart disease, or 
syndromic craniofacial anomalies.
After institutional review board approval, demographics, 
medical morbidities, and results of neurodevelopmental test-
ing were obtained from the hospital medical records. Post-
menstrual age was defined as the sum of birth gestational age 
and chronological age. For the children who participated in 
the National Institute of Child Health and Human Develop-
ment Neonatal Research Network (NRN) General Database 
and Follow-up study (inborn infants < 1000 g and/or < 27 
weeks) data were obtained from the NRN local registry and 
for those outside of this cohort, data was manually extracted 
from medical records. Each baby had undergone a polysom-
nogram prior to discharge from the neonatal intensive care 
unit. The indications for the PSG were clinical concern for 
significant upper airway obstruction or for oxygen titration 
in patients with BPD at term corrected age. BPD is one of 
the most common morbidities in premature neonates. Al-
though multiple definitions have been proposed, one com-
monly accepted version includes oxygen dependence at 28 
postnatal days and severity and stratification as mild, mod-
erate, or severe at 36 weeks postconceptual age (gestational 
age < 32 weeks) or at 56 days (gestational age > 32 weeks) 
based on supplemental oxygen delivery (ie, room air, frac-
tion of inspired oxygen (FiO2) 0.22–0.29, and FiO2 > 0.30, 
respectively).19 For the purpose of the study, we extracted 
the obstructive apnea-hypopnea index (AHI) from the medi-
cal records. Because most of the patients were on oxygen 
supplementation during the study, we did not include central 
or mixed apneas; their scoring was confounded by the pres-
ence of oxygen supplementation.
Polysomnography
PSGs were attended studies performed in the sleep laboratory 
and included the following monitoring parameters: electroen-
cephalogram (EEG), electrooculogram, chin electromyogram, 
electrocardiogram, thermistor and pressure transducer airflow 
signals, respiratory inductance plethysmography or thoracic 
impedance measurement (prior to 2007), continuous oxim-
etry, and end-tidal CO2 (ETCO2) monitoring. The collection 
software was Sandman v 9.0 (Embla systems LLC, Tonawa-
nda, New York, United States). Oxyhemoglobin saturation 
was measured via pulse oximetry (Masimo, Irvine, California, 
United States). ETCO2 was measured at the nose using BCI 
Capnocheck (Smiths Medical PM, Inc Waukesha, Wisconsin, 
United States) with side-stream sampling. Nasal airflow was 
acquired with a nasal cannula (Salter Labs, Arvin, California, 
United States).
PSGs were staged per scoring guidelines from Anders et 
al.20 Before 2007, the institutional criteria followed for scor-
ing respiratory events were: apnea for airflow limitation of 
80% or greater from baseline for at least 2 breaths and hy-
popneas for airflow limitation of 30% or greater for at least 2 
breaths duration associated with either ≥ 4% desaturation or 
an arousal. After 2007, the American Academy of Sleep Medi-
cine (AASM) respiratory rules for children were followed for 
scoring respiratory events.21 Before 2007, institutional criteria 
were followed for scoring arousals and awakenings. During 
non-rapid eye movement (Quiet & Indeterminate) sleep, arous-
als were scored as change in EEG frequency from theta to al-
pha or beta or from delta to theta, alpha, or beta for 3 seconds 
to 15 seconds. After 15 seconds, the EEG change was scored 
as an awakening. All gross body movements were scored as 
either arousals or awakenings consistent with the duration of 
the event. In rapid eye movement (Active) sleep, in addition 
to an EEG frequency change, an additional elevation of elec-
tromyogram amplitude during the event, was also required. 
After 2007, arousal index was scored as per AASM scoring 
criteria.21 PSGs were reviewed and reported by board-certified 
pediatric sleep medicine physicians.
OSA was defined as AHI > 1 event/h. Severe sleep apnea 
was defined as AHI > 15 events/h. Data on mean ETCO2, 
mean oxygen saturations, arousal index, and sleep efficiency 
were collected. If the study was performed on oxygen, the 
mean saturations on oxygen support was reported. Because 
of the physiological limitations of rapid respiratory rate, low 
tidal volume, the higher effect of apparatus dead-space in 
neonates, and the ventilation perfusion mismatch that affects 
patients with BPD, we defined hypoventilation as a mean 
ETCO2 ≥ 45 mm Hg.
Supplemental Oxygen Protocol
Oxygen titration goals were to maintain oxygen saturation 
(SaO2) at 90% or greater. If the baseline SaO2 was less than 
90%, for ≥ 5 minutes then supplemental oxygen was initiated 
and the level adjusted to maintain saturations > 90%.
1313 Journal of Clinical Sleep Medicine, Vol. 13, No. 11, 2017
A Bandyopadhyay, H Harmon JE Slaven, et al. Neurodevelopmental Outcomes of Neonatal OSA
Bayley Scales of Infant and Toddler Development
Toddler neurodevelopment was assessed with the BSID-III.22 
This validated tool uses developmental play tasks to compare 
motor, language, and cognitive development compared to stan-
dardized age norms.
Statistics
Univariate regression analysis was performed to find a relation-
ship between cognitive, language, and motor composite scores 
and neonatal course as well as PSG parameters (AHI and mean 
ETCO2). For significant outcomes on univariate analyses, we 
performed multivariate regression analysis. Pearson correla-
tion was performed to find a relationship between AHI and 
mean ETCO2. We divided the group based on mean ETCO2 
less than or equal to 45 mm Hg and compared the neonatal 
course, sleep study parameters and language, cognitive and 
motor scores between the 2 groups by Wilcoxon nonparamet-
ric rank-sum test and Fisher exact test, as applicable. Where 
conceptual models called for it, multivariable analyses were 
performed; although with the small sample size, models were 
performed with one covariate at a time using Bonferroni cor-
rections to control for type I error. Analyses were performed 
with SAS v9.4 (SAS Institute, Cary, North Carolina, United 
States).
RESULTS
Fifteen patients (males: n = 10) were eligible for the study. 
Baseline characteristics and neonatal intensive care course 
has been described in Table 1. Eleven patients (73%) were on 
oxygen support during PSG. Median AHI for the cohort was 
17.4 events/h (2.2–41.3). Median value of mean saturation was 
99% (94% to 99.8%). Median arousal index was 14 events/h 
(7.5–23.4). Median sleep efficiency was 83% (67.4% to 93.8%). 
Median ETCO2 during PSG was 47 mm Hg (25–60). The sleep 
apnea was obstructive in nature. Median age at performance 
of BSID-III testing was 22 months (corrected for prematu-
rity). Median cognitive composite score, language composite 
score, and motor composite score were 90 (interquartile range 
[IQR]:min-max 25: 65–125), 89 (IQR:min-max 32: 65–121) 
and 91 (IQR:min-max 16.75: 61–112, 1 missing data), respec-
tively, for the entire study sample.
AHI and mean ETCO2 correlation did not reach statisti-
cal significance. Mean ETCO2 negatively correlated with 
cognitive scores (P = .04) but not language or motor scores 
(Figure 1). AHI did not correlate with cognitive, language, or 
motor scores. In a multivariable model (using one covariate 
at a time to maintain power) after adjusting for birth gesta-
tional age, days on ventilator, days on oxygen and birth weight, 
a higher mean ETCO2 was associated with lower cognitive 
scores (P = .01). Table 2 is a comparison of baseline character-
istics, neonatal course, sleep study parameters, and language, 
motor, and cognitive scores in the study sample divided into 
2 groups based on mean ETCO2 < 45 or > 45 mm Hg. Median 
language and cognitive scores were significantly lower in the 
group with mean ETCO2 > 45 mm Hg.
DISCUSSION
This study suggests a high level of sleep apnea in preterm in-
fants with a high prevalence of BPD. Ours is the first study to 
explore the relationship between OSA and cognitive outcomes 
in preterm infants. Our study shows that the mean ETCO2 was 
associated with lower cognitive scores. A high mean ETCO2 
during PSG could potentially serve as a biomarker for pre-
dicting lower cognitive outcomes in this high-risk population. 
However, the median score for all 3 composite scores was still 
within one standard deviation of the published norm. There 
have been concerns that BSID-III testing may underestimate 
developmental delay.23,24 In the light of this knowledge, our 
Table 1—Baseline characteristics and neonatal course of the entire study population (n = 15).
Birth gestation age, weeks, median (IQR:min–max) 26 (1:24–34)
Birth weight, g, median (IQR:min–max) 830 (280:660–2010)
Sex, male, n (%) 10 (67)
Effective FiO2 ≥ 30% (defined by STOP-ROP data) at 36 weeks gestation, n (%) 9 (60)
Effective FiO2 at 36 weeks gestation, %, median (IQR:min–max) 30 (19:21–100)
Days on conventional ventilator, median (IQR:min–max) 12 (23:0–40)
Days on CPAP, median (IQR:min–max) 13 (20:0–52)
Days on oxygen, median (IQR:min–max) 110 (65:11–120)*
PDA requiring surgery, n (%) 2 (13)
Grade 1/2/3 intraventricular hemorrhage, n (%) 5 (33)
Periventricular leukomalacia, n (%) 0 (0)
Retinopathy of prematurity stage 3, n (%) 2 (13)
Presence of pharyngomalacia/laryngomalacia/tracheomalacia on bronchoscopy performed around the 
time of sleep study, n (%)
12 (80)
* = Neonatal Research Network registry stops counting after 120 days. CPAP = continuous positive airway pressure, FiO2 = fraction of inspired oxygen, 
IQR = interquartile range, max = maximum, min = minimum, PDA = patent ductus arteriosus, STOP-ROP = Supplemental Therapeutic Oxygen for 
Prethreshold Retinopathy of Prematurity.
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results may be underestimating poor cognitive, language, and 
motor outcome in these infants.
Despite excluding infants with severe neurological injury, 
tracheostomy, and severe retinopathy of prematurity, our 
patients remained highly morbid. Sixty percent of our patients 
were on greater than 30% FiO2 at 36 weeks of corrected age, 
consistent with severe BPD. Infants with BPD are known to 
suffer frequent episodes of hypoxemia and desaturations,25 
Figure 1—Relationship between cognitive composite score versus AHI and mean ETCO2.
AHI = apnea-hypopnea index, ETCO2 = end-tidal CO2.
Table 2—Comparison of baseline characteristics, neonatal course and sleep study parameters in the two groups based on 
mean ETCO2 < 45 mm Hg.
Mean 
ETCO2 < 45 mm Hg 
(n = 7)
Mean 
ETCO2 > 45 mm Hg 
(n = 8) P
Clinical Measures
Birth gestation age, weeks, median (min–max) 26 (25–34) 25.5 (24–26) .03
Birth weight, g, median (min–max) 1050 (770–2010) 805 (660–950) .04
Sex, male, n (%) 3 (43) 7 (88) .12
Effective FiO2 ≥ to 30% (defined by STOP-ROP data) at 36 weeks gestation, n (%) 3 (43) 6 (75) .31
Effective FiO2 at 36 weeks gestation, median (min–max) 0.21 (0.21–1.00) 0.30 (0.25–0.40) .48
Days on conventional ventilator, median (min–max) 5 (0–28) 18 (4–40) .04
Days on CPAP, median (min–max) 20 (0–52) 11.5 (0–48) .56
Days on oxygen, median (min–max) 55 (11–120) 120 (80–120) .02
PDA requiring surgery, n (%) 0 (0) 2 (25) .46
Grade 1/2/3 intraventricular hemorrhage, n (%) 1 (14) 4 (50) .16
Retinopathy of prematurity stage 3, n (%) 0 (0) 2 (25) .46
Presence of pharyngoamalacia/laryngomalacia/tracheomalacia on bronchoscopy 
performed around the time of sleep study, n (%)
6 (86) 6 (75) > .99
Postmenstrual age at the time of PSG, weeks, median (min–max) 40 (38–44) 41 (37–46) .81
PSG Measures
Apnea-hypopnea index, median (min–max) 16.2 (2.2–41.3) 17.8 (5.6–30) .86
Value for mean saturations, median (min–max) 97.8 (94–99.3) 99.15 (97.9–99.8) .05
Arousal index, median (min–max) 13.4 (7.5–23.4) 14.55 (7.6–20.8) .66
Sleep efficiency, median (min–max) 83.6 (67.4–92) 83 (74.7–93.8) .83
Neurodevelopmental Parameters
Cognitive score, median (min–max) 105 (85–125) 82.5 (65–100) .01
Language score, median (min–max) 100 (77–121) 75.5 (65–106) .04
Motor score, median (min–max) 91 (85–107) 91 (61–112) .65
CPAP = continuous positive airway pressure, ETCO2 = end-tidal CO2, FiO2 = fraction of inspired oxygen, max = maximum, min = minimum, PDA = patent 
ductus arteriosus, PSG = polysomnography, STOP-ROP = Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity.
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which could impair the development of cognitive functions.26 
Additionally, 80% of our patients had some form of airway ob-
struction confirmed by airway endoscopy (pharyngo/laryngo/
tracheomalacia) at the time of sleep study. Our patients had an 
elevated median AHI compared to published norms for chil-
dren,27 which supports existing data that preterm infants are 
more likely to have SDB.5,6,28 This may be multifactorial, in-
cluding upper airway obstruction29 and/or chronic lung paren-
chymal involvement with low pulmonary reserve. Our patients 
also had an elevated mean ETCO2, which could result from a 
combination of airway obstruction and ventilation perfusion 
mismatch secondary to BPD.
Seventy-three percent of our patients were on oxygen at the 
time of neonatal PSG. This may have led to underestimation 
of their uncorrected mean oxygen saturations. However, oxy-
gen supplementation typically will not prevent obstructive epi-
sodes from occurring and the infant may still experience upper 
airway obstructive events resulting in arousals and sleep frag-
mentation. As these patients were continuously being treated 
with oxygen, it is unlikely that prolonged uncorrected hypoxia 
contributed to the neurocognitive effect in our study. Our pa-
tients had increased AHI and arousal index as well as poor 
sleep efficiency, suggesting that despite oxygen supplementa-
tion, preterm neonates are at risk for adverse outcomes of sleep 
apnea. A review of the literature does not reveal normative 
data on arousal indices of neonates. In a study by Traeger et 
al.,30 arousal index in 2- to 9-year-old children was reported as 
8.8 ± 3.8 events/h (2.8–18.3). Our cohort had a higher arousal 
index with a sleep efficiency of 83%. Normative data on neo-
natal PSG is important to decide whether this elevated arousal 
index is a function of age or a manifestation of OSA. Regard-
less, this poor fragmentation of sleep may certainly affect 
cognitive outcomes.
It is known that sleep apnea can cause impaired execu-
tive functioning and behavior problems. Functional magnetic 
resonance imaging data in adults have suggested that SDB 
significantly alters functional connectivity in the cerebellar, 
frontal, parietal, temporal, occipital, limbic and basal ganglia 
regions. This impairment in network organization may result 
in altered responses in autonomic, cognitive, and sensorimo-
tor functions.31 Our results did not show any association be-
tween AHI and composite scores. Despite the significantly 
elevated AHI of our study sample, the cognitive scores were 
within one standard deviation of published norms. Although 
Ng and Chan32 have reviewed normative data on infant PSG, 
the reviewed studies do not include neonates. Therefore, what 
is considered severe OSA in the older child and is currently be-
ing extrapolated to neonates in clinical practice may not apply 
to neonates.33 However, we were limited by small sample size.
AHI and mean ETCO2 did not correlate significantly in 
our study, which is consistent with existing literature.34 It has 
been suggested that the utility of nocturnal capnometry may 
go beyond apnea detection and quantification of hypoventi-
lation syndromes. Instead it may reflect the balance of apnea 
and postapnea duration, which are not captured by AHI.35 Jai-
mchariyatam et al. suggested that nocturnal elevation of CO2 
may be due to a ventilatory impairment in the balance between 
accrual of CO2 (longer apnea duration) and more importantly 
the unloading of CO2 (longer postapnea duration). This study 
proposed use of exhaled CO2 as a physiological marker of dis-
ease severity that is independent of AHI.35
Our study had a high median ETCO2 (47, 25–60 mm Hg). 
Sixty percent of our patient sample had BPD. Permissive hy-
percapnia-intentionally allowing alveolar hypoventilation and 
increased partial pressure of carbon dioxide (PaCO2) has been 
advocated as a means to decrease ventilator-induced lung in-
jury and BPD.36 Existing literature suggests no effect of per-
missive hypercapnia on neurodevelopmental outcome.17,18 
Additionally, the Childhood Adenotonsillectomy, or CHAT, 
trial did not report any correlation of percentage of total sleep 
time (TST) with ETCO2 > 50 mm Hg with changes on the cog-
nitive and behavioral assessment at median age of 7.1 years. 
The median ETCO2, while asleep, of that study sample was 45 
mm Hg,34 which is a little lower than in our study. However, 
our study did show a significant association between noctur-
nal hypercarbia and cognitive composite scores. There are two 
significant points to consider. Most of the cited literature has 
correlated TST above ETCO2 > 50 mm Hg with neurodevel-
opmental outcome. In our study, we have utilized a separate 
measure (mean ETCO2) for correlation. The second point of 
interest is that in the study on infants with permissive hyper-
capnia,18 neurocognitive outcomes were correlated to arterial 
CO2 levels only within the first 14 days of life. However, in our 
study, ETCO2 was estimated at a median chronological age of 
4 months. Studies have demonstrated in adults that the current 
ETCO2 sampling devices may underestimate arterial CO2 by 
5–10 mm Hg, based on the pathophysiology of the patient.16,37,38 
This underestimation may be greater in children, who physi-
ologically have a higher respiratory rate, which may be further 
worsened with BPD. Additionally, the dilutional effect of any 
concurrent oxygen supplementation during ETCO2 measure-
ment could also have played a role. Thus, the arterial PaCO2 
may have been much higher in our sample of preterm infants, 
even when corrected to full term. An alternate definition from 
current polysomnographic pediatric hypoventilation criteria 
may therefore be necessary in neonates and young infants.
SDB encompasses a wide spectrum ranging from primary 
snoring to OSA. As per AASM guidelines, PSG criteria for pe-
diatric hypoventilation have been defined as at least 25% of TST 
with hypercapnia (PaCO2 > 50 mm Hg). However, we did not 
have consistent reporting of percentage of TST with hypercap-
nia in all PSG. We therefore used mean ETCO2 as a surrogate 
for hypoventilation. Paruthi et al. demonstrated that percent-
age TST ETCO2 > 50 mm Hg did not correlate with changes 
in cognitive or behavioral measures at 5 to 9.9 years of age.34 
Data on prematurity were not available for this study sample.34 
Based on our study results, mean ETCO2 may be a more sensi-
tive marker to detect cognitive outcome and its role should be 
explored further, particularly in the neonatal age group.
Limitations
Our study comprises a small cohort of preterm infants due to 
strict exclusion criteria and to exclude the confounding effects 
of known predictors of poor neurodevelopmental outcome. We 
did not have data on a repeat PSG prior to BSID-III testing to 
confirm persistence or resolution of SDB in the interim. We did 
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not have data on any interventions, such as adenoidectomy or 
tonsillectomy, performed between the PSG and BSID-III test-
ing. We were unable to correlate ETCO2 with blood gas CO2 
level at the time of PSG, as these data were unavailable. The 
coadministration of oxygen with CO2 during neonatal PSG 
could have introduced a dilutional effect of ETCO2 estimation. 
These are limitations of a retrospective study with access to 
existing available data. We also did not have consistent data 
on maternal education or socioeconomic status in our patients, 
which could play a role in the neurodevelopmental outcomes. 
Finally, this is the experience of a single center with institu-
tional practice biases that could affect the study results.
CONCLUSIONS
In conclusion, there is a high prevalence of SDB in preterm 
infants with dynamic airway collapse and bronchopulmonary 
dysplasia in the neonatal period. Mean ETCO2 negatively cor-
relates with cognitive outcome. Preterm neonates with SDB 
should be closely monitored for cognitive delays. This study 
highlights the importance of normative data on neonatal sleep 
apnea to better interpret thresholds of clinical significance.
ABBRE VI ATIONS
AASM, American Academy of Sleep Medicine
AHI, apnea-hypopnea index
BSID, Bayley Scales of Infant and Toddler Development
BPD, bronchopulmonary dysplasia
CO2, carbon dioxide
EEG, electroencephalogram
ETCO2, end-tidal CO2
FiO2, fraction of inspired oxygen
NEC, necrotizing enterocolitis
NRN, Neonatal Research Network
OSA, obstructive sleep apnea
PaCO2, partial pressure of carbon dioxide
PDA, patent ductus arteriosus
PSG, polysomnography
SDB, sleep-disordered breathing
TST, total sleep time
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